Windward Bio jumps 68% in US trading debut, Bloomberg reports

Bloomberg reports Windward Bio closed at $28.50, up 68% from its $17 IPO price. Reuters says the Novo Holdings-backed company raised $175 million in the IPO, with Sanofi agreeing to buy $50 million in shares and pre-funded warrants in a private placement. Windward is developing antibody treatments for respiratory and skin diseases, according to Reuters.